Resverlogix Corporation (RVX.TO) Updates Shareholders on Accelerated Clinical Trial Plan
10/16/2009 9:05:59 AM
More...
|
Resverlogix Corporation (RVX.TO) Appoints A. Brad Cann as Chief Financial Officer
10/13/2009 8:13:02 AM
More...
|
Resverlogix Corporation (RVX.TO) RVX-208 Second Clinical Trial Demonstrates Success on Key Reverse Cholesterol Transport Markers
9/29/2009 9:00:51 AM
More...
|
Resverlogix Corporation (RVX.TO) Notice of Conference Call Webcast to Discuss Clinical Trial Data
9/25/2009 10:50:03 AM
More...
|
Resverlogix Corporation (RVX.TO) Phase 1b/2a Study Meets Primary Endpoint
8/25/2009 8:19:46 AM
More...
|
Resverlogix Corporation (RVX.TO)'s Success in Inflammation Program Results in 2 Patents Filed
5/19/2009 11:12:14 AM
More...
|
Resverlogix Corporation (RVX.TO) Provides Quarterly Update
4/28/2009 9:07:51 AM
More...
|
Resverlogix Corporation (RVX.TO) Board of Directors Update
11/26/2008 9:20:29 AM
More...
|
Resverlogix Corporation (RVX.TO) Release: RVX-208 Data Demonstrates Increase in Functional HDL Particles
11/10/2008 11:15:56 AM
More...
|
Resverlogix Corporation (RVX.TO) Release: RVX-208 Exploratory Study Illustrates Early Potential for Alzheimer's Disease
11/10/2008 9:54:39 AM
More...
|
|